Showing 1 posts of 1 posts found.
AstraZeneca’s non-small cell lung cancer offering AZD9291 has been shown to delay disease progression by over a year. Data presented …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO